Jahn Beate, Arvandi Marjan, Rochau Ursula, Fiegl Heidi, Goebel Georg, Marth Christian, Siebert Uwe
Institute of Public Health, Medical Decision Making & Health Technology Assessment, Department of Public Health, Health Services Research & Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics & Technology, Hall in Tirol, Austria.
ONCOTYROL, Division of Health Technology Assessment & Bioinformatics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria.
J Comp Eff Res. 2017 Oct;6(7):563-574. doi: 10.2217/cer-2017-0015. Epub 2017 Sep 19.
To develop a prognostic score for primary breast cancer patients integrating conventional predictors and the novel biomarker CHAC1 to aid adjuvant chemotherapy decisions.
PATIENTS & METHODS: A prognostic score for overall survival was developed using: conventional predictors from a dataset of 1777 patients and the weight of CHAC1 mRNA expression from an independent dataset of 106 patients using multivariate Cox regression.
The new score includes: CHAC1 mRNA expression, age, tumor size, HER2 neu status, lymph node status and degree of malignancy. Using a cut-off value of 11 score points, 10-year survival was 82% in low-risk (n = 34) and 43% in high-risk patients (n = 72). The addition of CHAC1 resulted in 16% reclassification.
Including CHAC1 in prognostic prediction may aid (and change) personalized treatment selection.
开发一种用于原发性乳腺癌患者的预后评分系统，整合传统预测指标和新型生物标志物CHAC1，以辅助辅助化疗决策。
使用多变量Cox回归，基于1777例患者数据集中的传统预测指标以及106例患者独立数据集中CHAC1 mRNA表达的权重，制定总生存预后评分。
新的评分包括：CHAC1 mRNA表达、年龄、肿瘤大小、HER2 neu状态、淋巴结状态和恶性程度。采用11分的临界值，低风险患者（n = 34）的10年生存率为82%，高风险患者（n = 72）为43%。加入CHAC1后，重新分类的比例为16%。
将CHAC1纳入预后预测可能有助于（并改变）个性化治疗选择。
